Bile acid sequestrants for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia
Referencias
Additional references
Besseling J, Kindt I, Hof M, Kastelein JJ, Hutten BA, Hovingh GK. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis 2014;233(1):219‐23.
Betteridge DJ, Bhatnager D, Bing RF, Durrington PN, Evans GR, Flax H, et al. Treatment of familial hypercholesterolaemia. The United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ 1992;304(6838):1335‐8.
Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Archives of Internal Medicine 1999;159(16):1893‐900.
Davidson MH. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. Journal of Clinical Lipidology 2011;5(2):76‐81.
Deeks JJ, Higgins JPT, Altman DG, editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analysis. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Einarsson K, Ericsson S, Ewerth S, Reihnér E, Rudling M, Ståhlberg D, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. European Journal of Clinical Pharmacology 1991;40 Suppl 1:53‐8.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.
Higgins JPT, Altman DG, Sterne JAC, editor(s) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ, Altman DG, editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from handbook.cochrane.org.
Insull W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. Southern Medical Journal 2006;99(3):257‐73.
Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic yield of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. Journal of the American College Cardiology 2016;67(22):2578‐89.
Lotta LA, Sharp SJ, Burgess S, Perry JR, Stewart ID, Willems SM, et al. Association between low‐density lipoprotein cholesterol‐lowering genetic variants and risk of type 2 diabetes: a meta‐analysis. JAMA 2016;316(13):1383‐91.
Marina AL, Utzschneider KM, Wright LA, Montgomery BK, Marcovina SM, Kahn SE. Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β‐cell function. Diabetes Care 2012;35(5):1119‐25.
Mazidi M, Rezaie P, Karimi E, Kengne AP. The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: a systematic review and meta‐analysis of randomized controlled trials. International Journal of Cardiology 2017;15(227):850‐7.
Miller NE, Cifton‐Bligh P, Nestel PJ. Effects of colestipol, a new bile acid sequestering resin on cholesterol metabolism in man. Journal of Laboratory and Clinical Medicine 1973;82(6):876‐90.
Moutafis CD, Simons LA, Myant NB, Adams PW, Wynn V. The effect of cholestyramine on the faecal excretion of bile acids and neutral steroids in familial hypercholesterolaemia. Atherosclerosis 1977;26(3):329‐34.
Mundal L, Sarancic M, Ose L, Iversen PO, Borgan JK, Veierød MB, et al. Mortality among patient with familial hypercholesterolaemia: a registry‐based study in Norway, 1999‐2010. JAMA 2014;3(6):e001236.
Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European Heart Journal 2013;34(45):3478‐90a.
Pasternak RC, Smith SC, Bairey‐Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Journal of the American College of Cardiology 2002;40(3):567‐72.
Potthoff MJ, Potts A, He T, Duarte JA, Taussig R, Mangelsdorf DJ, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5‐mediated induction of GLP‐1 action in DIO mice. American Journal of Physiology. Gastrointestinal and Liver Physiology 2013;304(4):371‐80.
Rosenstock J, Hernandez‐Triana E, Handelsman Y, Misir S, Jones MR, Nagendran S. Initial combination therapy with metformin plus colesevelam in drug‐naïve Hispanic patients with early type 2 diabetes. Postgraduate Medicine 2012;124(4):7‐13.
Ross S, D'Mello M, Anand SS, Eikelboom J, CARDIoGRAMplusC4D Consortium, Stewart AF, et al. Effect of bile acid sequestrants on the risk of cardiovascular events: a Mendelian randomization analysis. Circulation. Cardiovascular Genetics 2015;8(4):618‐27.
Ryan A, Byrne CD. Importance of early recognition of heterozygous familial hypercholesterolaemia. Current Opinion in Lipidology 2015;26(4):298‐303.
Shemilt I, Mugford M, Byford S, Drummond M, Eisenstein E, Knapp M, et al on behalf of the Campbell and Cochrane Economics Methods Group. Chapter 15: Incorporating economics evidence. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Shepherd J, Packard CJ, Bicker S, Lawrie TD, Morgan HG. Cholestyramine promotes receptor mediated low‐density lipoprotein catabolism. New England Journal of Medicine 1980;302(22):1219‐22.
Slack J. Risks of ischaemic heart disease in familial hyperlipoproteinaemic states. Lancet 1969;2(7635):1380‐2.
Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974;49(3):476‐88.
Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD004816.pub5]
EAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo‐Vaz AJ, Akram A, Kondapally Seshasai SR, Cole D, Watts GF, et al. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis. Supplements 2016;22:1‐32.
Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.
Yamakawa T, Takano T, Utsunomiya H, Kadonosono K, Okamura A. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocrine Journal 2007;54(1):53‐8.
